276 related articles for article (PubMed ID: 19241422)
1. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
Ramondetta LM; Johnson AJ; Sun CC; Atkinson N; Smith JA; Jung MS; Broaddus R; Iyer RB; Burke T
Cancer; 2009 May; 115(9):1867-74. PubMed ID: 19241422
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin.
Burke TW; Munkarah A; Kavanagh JJ; Morris M; Levenback C; Tornos C; Gershenson DM
Gynecol Oncol; 1993 Dec; 51(3):397-400. PubMed ID: 8112651
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: a phase II study.
Pinelli DM; Fiorica JV; Roberts WS; Hoffman MS; Nicosia SV; Cavanagh D
Gynecol Oncol; 1996 Mar; 60(3):462-7. PubMed ID: 8774658
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.
Dahhan T; Fons G; Buist MR; Ten Kate FJ; van der Velden J
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):80-4. PubMed ID: 19269732
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
Check JH; Dix E; Cohen R; Check D; Wilson C
Anticancer Res; 2010 Feb; 30(2):623-8. PubMed ID: 20332480
[TBL] [Abstract][Full Text] [Related]
6. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
7. [Treatment and prognosis of low-grade malignant endometrial stromal sarcoma].
Ma SK; Zhang HT; Wu LY; Liu LY; Li B
Zhonghua Zhong Liu Za Zhi; 2007 Jan; 29(1):74-8. PubMed ID: 17575701
[TBL] [Abstract][Full Text] [Related]
8. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Grunberg SM; Weiss MH; Russell CA; Spitz IM; Ahmadi J; Sadun A; Sitruk-Ware R
Cancer Invest; 2006 Dec; 24(8):727-33. PubMed ID: 17162554
[TBL] [Abstract][Full Text] [Related]
9. A multi-institutional review of outcomes of endometrial stromal sarcoma.
Leath CA; Huh WK; Hyde J; Cohn DE; Resnick KE; Taylor NP; Powell MA; Mutch DG; Bradley WH; Geller MA; Argenta PA; Gold MA
Gynecol Oncol; 2007 Jun; 105(3):630-4. PubMed ID: 17320937
[TBL] [Abstract][Full Text] [Related]
10. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
Ramirez PT; Frumovitz M; Bodurka DC; Sun CC; Levenback C
Gynecol Oncol; 2004 Oct; 95(1):133-8. PubMed ID: 15385122
[TBL] [Abstract][Full Text] [Related]
11. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
12. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
13. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer.
Yamazawa K; Hirai M; Fujito A; Nishi H; Terauchi F; Ishikura H; Shozu M; Isaka K
Hum Reprod; 2007 Jul; 22(7):1953-8. PubMed ID: 17449880
[TBL] [Abstract][Full Text] [Related]
14. Endometrial stromal sarcoma: objective response to letrozole.
Maluf FC; Sabbatini P; Schwartz L; Xia J; Aghajanian C
Gynecol Oncol; 2001 Aug; 82(2):384-8. PubMed ID: 11531300
[TBL] [Abstract][Full Text] [Related]
15. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
16. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue.
Burke C; Hickey K
Obstet Gynecol; 2004 Nov; 104(5 Pt 2):1182-4. PubMed ID: 15516445
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
18. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata.
Eisinger SH; Fiscella J; Bonfiglio T; Meldrum S; Fiscella K
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):215-8. PubMed ID: 19586708
[TBL] [Abstract][Full Text] [Related]
19. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
Grendys EC; Blessing JA; Burger R; Hoffman J
Gynecol Oncol; 2005 Aug; 98(2):249-53. PubMed ID: 15978659
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of prognostic factors in uterine endometrioid adenocarcinoma of various grade.
Dvalishvili I; Charkviani L; Turashvili G; Burkadze G
Georgian Med News; 2006 Mar; (132):24-7. PubMed ID: 16636372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
